Module 04G · Lesson 01

Regulatory Affairs — Where AI Fits in Your Workflow

Reading time: 20 minutes Track: Role Path — Regulatory Affairs Prerequisites: Modules 01, 02, 03 complete Audience: Regulatory affairs strategists, regulatory writers, regulatory project managers, CMC regulatory specialists, regulatory operations professionals

What this lesson does

Regulatory affairs is the function with the most direct interaction with FDA, EMA, and other health authorities. The work is high-stakes, document-heavy, precedent-driven, and deeply technical. Mistakes have outsized consequences — failed submissions, regulatory holds, delayed approvals, and worst case, patient harm or product withdrawal.

AI's potential here is enormous and the risks are correspondingly large. This module navigates both honestly.

By the end of this lesson, you'll be able to:

Identify the workflows in regulatory affairs where AI most reliably saves time
Recognize the specific regulatory constraints that shape AI use
Build a personal prompt library for your daily artifacts
Set realistic expectations — particularly about what AI does and doesn't do in regulatory work

01 · The regulatory affairs AI reality

A specific challenge for regulatory AI: this is the function where conservatism is most warranted, and where conservatism shades easiest into paralysis. Many regulatory teams are still defaulting to "no AI" because the consequences of getting it wrong feel catastrophic.

That posture protects you from one class of risk and exposes you to another: falling behind organizations that are figuring out AI use carefully. The right posture is calibrated use, not blanket avoidance.

What AI is reliably useful for in regulatory:

Drafting non-submission internal documents (meeting prep, internal memos, situation analyses)
Drafting first versions of submission sections (with heavy verification)
Summarizing long documents (guidance documents, prior submissions, advisory committee minutes)
Comparing regulatory positions across regions (US vs. EU vs. Japan)
Building regulatory strategy frameworks
Drafting responses to agency questions (with heavy verification)
Reviewing draft documents for completeness against guidance
Project management documents
Training materials for non-regulatory colleagues
Translation between regulatory and other functions

What AI is not reliably useful for:

Final submission content without thorough verification
Real-time agency interaction decisions
Definitive interpretation of regulation or guidance
Strategic decisions about regulatory pathway
Anything where current and accurate regulation knowledge is critical (knowledge cutoff matters)

The opportunity is genuine; the discipline must be tight.

02 · The eight core workflows

Workflow 1 — Internal regulatory documents

Internal memos, situation analyses, regulatory updates to leadership, training documents.

Where AI helps: Drafting structured analyses, ensuring completeness, translating between regulatory and other functions.

Risk profile: Lower than submission work; standard enterprise AI handling appropriate.

Workflow 2 — Submission section drafting

Drafting sections of INDs, NDAs, BLAs, supplements, briefing documents.

Where AI helps: Producing structured first drafts, ensuring all required elements per guidance, consistency across sections.

Risk profile: High. Requires zero-retention enterprise environment or on-premises, heavy verification, and adherence to your organization's AI-in-submissions policy (if one exists).

Workflow 3 — Regulatory intelligence

Monitoring guidance, advisory committee outcomes, recent approvals, competitor activity.

Where AI helps: Summarizing long documents (advisory committee transcripts, guidance documents), comparing regulatory positions across regions.

Risk profile: Moderate. Knowledge cutoff means AI may miss the most recent developments; supplement with current sources.

Workflow 4 — Health authority interaction preparation

Pre-meeting prep, briefing document drafting, anticipating questions, preparing responses.

Where AI helps: Question anticipation, draft response generation, mock Q&A.

Risk profile: High. Briefing documents are pre-decisional content (Tier 4); use only in appropriate environments.

Workflow 5 — Comparative regulatory analysis

Comparing regulatory positions across regions, time periods, similar products.

Where AI helps: Structured comparison frameworks, drafting analyses.

Risk profile: Moderate. Verification against primary sources critical.

Workflow 6 — Response to agency questions

Drafting responses to FDA/EMA/other agency questions, deficiency letters, IRs.

Where AI helps: Structuring responses, ensuring all questions addressed, drafting first versions.

Risk profile: Very high. Responses go to agencies; errors have direct regulatory consequences. Heavy verification non-negotiable.

Workflow 7 — Cross-functional translation

Explaining regulatory considerations to non-regulatory colleagues; translating their work into regulatory language.

Where AI helps: Audience-appropriate explanations, draft translations.

Risk profile: Lower than direct regulatory work but content-dependent.

Workflow 8 — Regulatory strategy documents

Strategy memos, pathway analyses, scenario planning documents.

Where AI helps: Framework development, scenario generation, structured analyses.

Risk profile: High due to confidentiality of strategic content (Tier 3+).

03 · The data classification challenge for regulatory affairs

Regulatory work touches some of the most sensitive data in biotech.

Tier 1 — Public: Published guidance documents, public advisory committee materials, public agency announcements, approved labels.

Tier 2 — Internal: Internal regulatory SOPs, training, organizational documents.

Tier 3 — Confidential: Pre-public regulatory strategy, comparative analyses about your programs, internal regulatory updates not yet released.

Tier 4 — Restricted: Pre-submission content, draft briefing documents, agency correspondence, draft submissions, regulatory intelligence about your specific programs, internal positions on agency feedback.

Tier 5 — Prohibited: Trade-secret regulatory strategies, attorney-client privileged regulatory legal content, anything covered by specific agency confidentiality provisions.

The regulatory-specific risks:

The pre-submission leak. Pre-submission content is essentially always Tier 4. Even discussing the strategy abstractly can leak information. Default: zero-retention environments only for pre-submission work.
The "guidance document" trap. Public guidance documents are Tier 1. Your interpretation of them in the context of your program is Tier 3+. Don't conflate.
The competitor analysis problem. Comparing your program to a competitor's involves both publicly available competitor information (Tier 1) and your analysis (Tier 3). Treat the analysis as Tier 3.
The advisory committee preparation issue. Materials prepared for advisory committees are typically eventually public but are pre-decisionally confidential. Treat as Tier 4 until public.

The regulatory affairs default: Zero-retention enterprise environments (Bedrock with private endpoint, equivalent) for any pre-submission, agency-interaction, or strategy work. Standard enterprise for internal and intelligence work. Consumer AI only for fully public content.

04 · The verification habits for regulatory work

Regulatory work has the most demanding verification requirements in biotech AI use.

Factual verification

For any AI-generated regulatory content:

Verify guidance document references (exact citation, current version)
Verify regulation citations (correct CFR, correct subsection)
Verify precedent claims (the agency action you're citing actually happened as described)
Verify quantitative claims (sample sizes, timelines, dose ranges from prior submissions)
Verify cross-references to other submission documents

Currency verification

For any regulatory content where currency matters:

Verify guidance is the current version (FDA has new guidance regularly)
Verify regulation is current text (regulations change)
Verify recent agency positions are reflected (newer than knowledge cutoff)

This is where AI's knowledge cutoff matters most. For anything recent, you supplement with current sources.

Completeness verification

For submission content:

Verify all required elements per the relevant guidance
Verify cross-references to other modules / sections
Verify required tables and figures
Verify standard format compliance

Policy compliance verification

For any regulatory AI use:

Verify your organization's policy on AI in regulatory submissions
Verify documentation requirements (some organizations require formal logs of AI use in submissions)
Verify disclosure requirements (some organizations require disclosure of AI use in submission cover letters)

05 · The "AI in regulatory submissions" policy question

A specific issue worth addressing directly: what is your organization's policy on AI use in regulatory submissions?

As of late 2025, organizations cluster into three positions:

Position 1 — Effectively prohibited. AI is not used for any submission content. Some organizations have explicit policies; others have policies-in-practice driven by senior leadership conservatism.

Position 2 — Permitted with controls. AI use is allowed for submission content under specific conditions: approved environments, mandatory verification protocols, documented logs, sometimes mandatory senior review of AI-touched sections.

Position 3 — Encouraged with controls. AI use is encouraged where it improves quality or speed, under the same controls as Position 2.

The trajectory: Most organizations are moving from Position 1 toward Position 2 over the next 12-24 months. The driver: competitive pressure plus growing evidence that controlled use produces better outcomes than blanket avoidance.

Your action: Know your organization's position. If you don't know, ask. If your organization is at Position 1, recognize that personal AI use on submission content may violate policy even if it would improve the work.

If you're in a position to influence policy, the question worth raising is: what controls would make AI use acceptable for this organization, given the genuine value at stake?

06 · A worked example

A realistic scenario.

Setting: You're preparing for a Type C meeting with FDA on a specific aspect of your clinical development program. You need to draft the briefing document.

Step 1 — Confirm AI policy

Confirm your organization's policy for AI in pre-meeting briefing documents. Assuming Position 2 (permitted with controls): proceed.

Step 2 — Initial structure

Open zero-retention enterprise AI environment.

Senior regulatory strategist preparing a Type C meeting briefing document. Topic: [specific topic]. Target audience: FDA reviewers in [division]. Meeting purpose: [obtain agency feedback on specific approach].

Draft the briefing document structure following FDA Type C meeting guidance:
1. Introduction
2. Background
3. Issues for discussion (with specific questions)
4. Proposed approach
5. Supporting data
6. Specific questions for agency feedback
7. References

For each section, list the content that should be addressed.

Don't draft the content yet — I'll provide details for each section.

Get structure. Verify against current FDA Type C guidance.

Step 3 — Section-by-section drafting

For each section, provide your specific content and prompt for drafting.

For introduction and background:

Provide context, prior interactions, current status
AI drafts; you verify against actual history

For issues for discussion:

Provide your specific questions and rationale
AI structures; you verify the questions are sharp and complete

For proposed approach:

Provide your strategy
AI drafts; you verify it accurately reflects your position

For supporting data:

This is where verification is most critical
Provide specific data, AI structures
Verify every number, every citation, every cross-reference

Step 4 — Adversarial review

Senior FDA reviewer in [division]. Review the following briefing document. Identify:
1. Questions the agency is likely to ask that aren't addressed
2. Positions that may be challenged
3. Inconsistencies with prior interactions or guidance
4. Specific data the agency will look for that isn't included
5. Areas where the proposed approach may need adjustment based on agency precedent

[Draft attached]

Use the response to strengthen the draft.

Step 5 — Senior review

Per your organization's SOP, senior regulatory review of AI-touched content.

Step 6 — Documentation

Document AI use:

Tool, model, environment
Date of drafting
Sections involved
Verification steps performed
Reviewer signoff

Total time: ~40% reduction in drafting time. Verification time approximately the same. Quality at or above standard.

07 · What you'll build through this module

The remaining lessons in Module 04G:

Lesson 02 · Submission section drafting and verification — the highest-stakes workflow
Lesson 03 · Health authority interaction prep — strategic regulatory work
Lesson 04 · Regulatory intelligence and comparative analysis — the analytical workflows
Lesson 05 · Capstone — your regulatory affairs AI playbook

08 · Knowledge check

Three questions.

Q1. What's the most accurate characterization of AI's current role in regulatory affairs?

a) AI can replace most regulatory work b) The opportunity is genuine but the discipline must be tight — calibrated controlled use produces better outcomes than blanket avoidance, with appropriate environments and verification c) AI shouldn't be used in regulatory affairs d) AI is only useful for non-submission work

Q2. Why is the "trajectory from Position 1 to Position 2" specifically called out?

a) FDA mandates it b) Most organizations are moving from "effectively prohibited" toward "permitted with controls" over 12-24 months, driven by competitive pressure and evidence that controlled use produces better outcomes than blanket avoidance c) Position 2 is universally adopted already d) It's a regulatory requirement

Q3. What's the appropriate default AI environment for pre-submission regulatory work?

a) Consumer AI is fine for drafting b) Standard enterprise AI c) Zero-retention enterprise environments only, with heavy verification and adherence to organizational policy d) Avoid AI entirely

Answers: Q1: b · Q2: b · Q3: c

09 · What's next

Lesson 02: Submission section drafting and verification.

End of Module 04G · Lesson 01.